A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

@article{Pierga2009AMR,
  title={A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients},
  author={J -Y. Pierga and Suzette Delaloge and Marc Espie and Etienne G. C. Brain and Brigitte Sigal-Zafrani and Marina V. Mathieu and Philippe Bertheau and Jean Marc JM Guinebreti{\`e}re and Miriam Spielmann and Alexia Savignoni and Michel M. Marty},
  journal={Breast Cancer Research and Treatment},
  year={2009},
  volume={122},
  pages={429-437}
}
To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addition of celecoxib in HER2 negative patients or trastuzumab in HER2 positive patients. From May 2004 till October 2007, 340 patients with stage II and III breast adenocarcinoma, ineligible for breast conserving surgery, received eight sequential three weekly cycles of EC-D [epirubicin (75 mg/m2)–cyclophosphamide (750 mg/m2) for four cycles followed by docetaxel (100 mg/m2) for… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Similar Papers

Loading similar papers…